First Commonwealth Finl (NYSE:FCF) reported quarterly earnings of $0.39 per share which missed the analyst consensus estimate of $0.43 by 9.3 percent. This is a 5.41 percent increase over earnings of $0.37 per share from the same period last year.
VYNE Therapeutics Shares Disappointing Data From Atopic Dermatitis Trial
VYNE Therapeutics Inc (NASDAQ: VYNE) has announced results from the Phase 2a segment of Phase 1b/2a trial evaluating FMX114 for mild-to-moderate atopic dermatitis.
